---

SOLITARY PULMONARY NODULE (SPN) - The Complete Master Guide

---

1. DEFINITION - GET THIS EXACT

• A single, round or oval radiographic opacity in the lung parenchyma
• ≤3 cm in diameter (lesions >3 cm are called "pulmonary masses" and carry a much higher malignancy risk)
• Completely surrounded by normal aerated lung
• No associated mediastinal adenopathy, atelectasis, or pleural effusion

Professor-level nuance: The word "solitary" was coined in the CXR era. With CT, up to 50% of what appears solitary on CXR actually has companion sub-centimeter nodules. The term "solitary" strictly requires CT confirmation. In the Early Lung Cancer Action project, ~7% of healthy volunteers had 1-3 nodules, and 25% had up to 6. So always say "as evaluated by CT."

---

2. HISTORICAL EVOLUTION - "THE PAST"

The "Coin Lesion" Era (1940s-1960s)

• The SPN was originally called a "coin lesion" when first described on plain CXR
• Initial case series showed high malignancy rates (up to 40%) among resected nodules - but these were surgical series bias (only the suspicious ones got operated)
• Most pre-CT nodules were >10 mm and "presumed cancer until proven otherwise," leading to massive over-surgery of benign lesions
• The link between smoking and lung cancer in the mid-1960s sparked the first screening programs with CXR

CT Revolution (1980s)

• Chest CT in the 1980s became widespread and "accidentally launched an epidemic of incidental findings" - Fishman's
• CT use increased ~8% per year between 1996-2010; by 2008 there were 23 chest CTs per 1000 enrollees per year
• One landmark study: in >28% of diagnostic chest CTs, at least one nodule measuring 4-30 mm was found
• This meant clinicians suddenly had millions of small nodules they had no framework to handle

NLST and Screening Era (2000s-2010s)

• The National Lung Screening Trial (NLST) proved low-dose CT (LDCT) reduces lung cancer mortality
• It simultaneously created the "nodule epidemic" - on baseline screening, 20-50% of subjects had at least one nodule
• But only 3-12% of screen-detected nodules on the first round were malignant - 90-95% were false positives
• This created massive anxiety, unnecessary procedures, and drove the creation of formal management guidelines

In the US: ~1 million new SPNs detected per year currently

---

3. EPIDEMIOLOGY & SIGNIFICANCE

---

4. CLASSIFICATION BY DENSITY (CT Attenuation) - CRITICAL

A. Solid Nodule

• Completely masks underlying lung parenchyma
• Classic presentation; most common type
• Management follows size-based Fleischner criteria

B. Ground-Glass Opacity/Nodule (GGO/GGN) - Nonsolid

• Hazy increased attenuation that does NOT obscure underlying bronchi/vessels
• Lung parenchyma still visible through it
• More likely to be indolent - longer volume doubling times
• Histologic spectrum: Atypical Adenomatous Hyperplasia (AAH) → Adenocarcinoma in Situ (AIS) → Minimally Invasive Adenocarcinoma (MIA) → Invasive Adenocarcinoma
• AAH: usually <5 mm, minimally hazy
• AIS: slightly more opaque than AAH, typically nonsolid on thin-section CT
• MIA: mainly solid with a small (<5 mm) central solid component

C. Part-Solid (Semisolid) Nodule

• Both ground-glass AND solid components
• Solid component represents the invasive portion
• HIGHEST risk of malignancy among all three types
• 40-50% of part-solid subcentimeter lesions are malignant vs. only 15% of subcentimeter solid or nonsolid nodules
• Management driven by the SIZE OF THE SOLID COMPONENT

Pearl for professors: Ask them - "If I find a 12 mm part-solid nodule with a 4 mm solid component and a 12 mm part-solid nodule with an 8 mm solid component - are they managed the same?" Answer: No. The solid component size drives the management algorithm.

---

5. DIFFERENTIAL DIAGNOSIS - BROAD BUT SYSTEMATIC

Malignant Causes

• Primary lung cancer (most important - adenocarcinoma > squamous > small cell > large cell)
• Carcinoid tumor (typical and atypical; often central, highly vascular)
• Pulmonary metastasis from: breast, colon, kidney, melanoma, sarcoma, germ cell tumors

Key point: A new single pulmonary nodule in a patient with prior malignancy. Likelihood of it being a NEW primary lung cancer (not metastasis) is highest with prior: uterine (74%), bladder (89%), lung (92%), and head & neck (94%) carcinomas.

Benign Causes

• Tuberculosis
• Histoplasmosis (endemic - Ohio/Mississippi valley)
• Coccidioidomycosis (endemic - American Southwest)
• Dirofilariasis (dog heartworm - underdiagnosed!)
• Mycetoma, Echinococcal cyst, Ascariasis

• Sarcoidosis (not always accompanied by hilar adenopathy)
• Rheumatoid arthritis (necrobiotic nodules - can coexist with subcutaneous nodules)
• Granulomatosis with Polyangiitis/GPA (Wegener's) - often cavitary, multiple, ± renal/sinus disease
• Inflammatory Bowel Disease

• Pulmonary hamartoma (2nd most common single benign cause, ~10%) - "popcorn" calcification, fat density (-40 to -120 HU), diagnostic on CT in ~50%
• Rounded pneumonia
• Pseudotumor (fluid in interlobar fissure - disappears with diuresis!)
• AVM (arteriovenous malformation)
• Pulmonary sequestration
• Intrapulmonary lymph node (perifissural location, lentiform shape)
• Inflammatory myofibroblastic tumor

---

6. RADIOLOGY - THE CORE SKILL

CXR First, Then CT

• Size, shape, density
• Calcification pattern
• Margin characteristics
• Fat content
• Satellite nodules
• Number/location

CT Characteristics: BENIGN vs. MALIGNANT

Only 2 criteria definitively predict benignity: (1) no growth for >2 years, and (2) benign calcification pattern. - Harrison's 22e

Professor-level nuance on pleural tail: Once thought to suggest malignancy, it is now recognized as a non-specific finding that can be seen in both benign and malignant nodules. Murray & Nadel explicitly states this.

Eccentric calcification: This does NOT mean benign - cancer can engulf a pre-existing calcified granuloma and show eccentric/stippled calcium. This is one of the most common exam traps.

Volume Doubling Time (VDT)

• Lung cancers: VDT = 20 to 400 days
• VDT <20 days = infection (too fast for cancer)
• VDT >400 days = suggests benign, but can still be slow-growing cancer (especially GGO-type adenocarcinomas!)
• 2D diameter underestimates growth; volumetric analysis (3D) is more accurate and is preferred in BTS guidelines

---

7. PROBABILITY OF MALIGNANCY - RISK MODELS

Clinical Risk Factors (Independent Predictors - Mayo Clinic Model)

1. Older age
2. Cigarette smoking history
3. Prior cancer diagnosis (especially >5 years before)
4. Nodule diameter (larger = more likely malignant)
5. Spiculation on CT
6. Upper lobe location

Risk Stratification Categories

• Low probability: <5% chance of malignancy
• Moderate probability: 5-65%
• High probability: >65%

The Brock Model (also called "PanCan model" from the Pan-Canadian Early Detection Study): Includes nodule type (solid vs. sub-solid), family history of lung cancer, nodule count. This is used in BTS and BCCA guidelines. Good question to ask professors: "Does the Mayo model or the Brock model incorporate sub-solid nodule characteristics?" - Brock does, Mayo doesn't (it predates modern CT classification).

---

8. DIAGNOSTIC WORKUP - STEP BY STEP

Step 1: Get old films

Step 2: CT Characterization

• Nodule size, density, margins, calcification
• Look for satellite nodules, lymphadenopathy
• Contrast enhancement: benign nodules enhance <15 HU; most malignant nodules enhance >20 HU (contrast CT enhancement study - less commonly used now)

Step 3: FDG-PET / PET-CT

• Sensitivity: 87-97%
• Specificity: 78-82%
• PPV: ~91%
• NPV: ~90%

• Adenocarcinoma in situ / minimally invasive adenocarcinoma
• Mucinous adenocarcinoma
• Carcinoid tumors (low metabolic activity)
• Nodules <8 mm (spatial resolution limit)
• Hyperglycemia (competes with FDG)

• Active TB granuloma
• Histoplasmosis
• Aspergillosis
• Sarcoidosis
• Rheumatoid nodules

Step 4: Tissue Sampling Options

• Best for peripheral nodules, >1 cm
• Sensitivity 80-95%
• Complication: pneumothorax (10-30%; ~5% require chest tube)
• Non-diagnostic result does NOT exclude malignancy

• Best for central/endobronchial lesions
• Sensitivity for peripheral nodules is low (~20-30% for <2 cm nodules) with conventional bronchoscopy
• Endobronchial Ultrasound (EBUS): For nodules with airway proximity
• Electromagnetic navigation bronchoscopy (ENB): Newer modality for peripheral nodules, improves yield to ~60-80%
• Robotic bronchoscopy (e.g., Monarch, Ion systems): Cutting edge; navigates to peripheral nodules

• Diagnostic AND therapeutic in one procedure
• For nodules with high probability of malignancy (>65%) OR indeterminate after all non-invasive workup
• If nodule is too deep for VATS, CT-guided hookwire localization or dye injection can mark the target preoperatively

---

9. MANAGEMENT GUIDELINES - THE FLEISCHNER SOCIETY 2017 (Gold Standard)

Solid Nodules

Major change from previous Fleischner: The 2017 version raised the no-follow-up threshold from 4 mm to 6 mm in low-risk patients. This eliminates thousands of unnecessary follow-up scans per year. Rationale: Cancer risk in nodules <6 mm is considerably less than 1% even in high-risk patients.

Subsolid Nodules (2017 Fleischner)

Why 5-year follow-up for GGOs? Because subsolid nodules grow MUCH more slowly. Volume doubling times can be years, not months. A GGO that appears stable at 2 years can still become invasive cancer years later. This is the biology of the AAH → AIS → MIA → invasive adenocarcinoma spectrum. They essentially start as non-malignant cells that transform over years.

Lung-RADS (ACR) - for Screening Programs

---

10. WHAT HAPPENS WHEN TISSUE IS NEEDED - SURGERY

• Lobectomy is the standard of care for resectable lung cancer
• VATS lobectomy has largely replaced open thoracotomy for most cases
• Wedge resection/segmentectomy: For small peripheral nodules or patients with poor pulmonary reserve
• Anatomic resection (lobectomy) has better local control and survival than wedge resection for invasive cancers

• Pulmonary metastasectomy - the IRLM (International Registry of Lung Metastases) data: 5-year survival after complete resection is 36% for all tumor types
• Best outcomes: germ cell tumors, disease-free interval >36 months, single metastasis

---

11. THE FUTURE - WHERE SPN MANAGEMENT IS HEADING

1. Artificial Intelligence and Deep Learning

• AI algorithms now achieve radiologist-level performance in nodule detection and characterization
• Deep learning models can predict malignancy risk from CT features alone with AUC >0.95
• Multi-institutional AI validation studies are ongoing
• Future: AI-integrated reporting that auto-classifies every nodule and generates a follow-up plan

2. Liquid Biopsy

• Circulating tumor DNA (ctDNA) and cell-free DNA can potentially be detected even for small cancers
• GRAIL Galleri test and similar assays detect multi-cancer early detection signals from a blood draw
• Currently insufficient sensitivity for sub-cm nodules, but improving rapidly
• Could replace some invasive tissue sampling for risk stratification

3. Proteomics and Biomarker Panels

• MiR-Test (microRNA panel) and Nodify XL2 (plasma protein panel) are commercially available in some markets
• Nodify XL2 (LG3BP + C163A) combined with clinical/CT data: when test indicates low risk (<50% pretest probability), can safely defer invasive testing
• Useful when the pretest probability is intermediate (5-65%) - can reclassify to low or high, guiding whether to biopsy

4. Radiomics

• Extraction of hundreds of quantitative features from CT images (texture, entropy, heterogeneity, wavelets)
• Combined with machine learning to predict malignancy, histology, and mutation status (e.g., EGFR, KRAS)
• Can potentially non-invasively predict molecular subtypes guiding targeted therapy decisions

5. Robotic Bronchoscopy

• Systems like the Monarch (J&J) and Ion (Intuitive) platforms enable ultra-peripheral nodule access
• Can reach 6th-generation bronchi for biopsy
• Real-time imaging guidance, reduced need for CT-guided TTNB

6. Lung Cancer Screening Expansion

• Current USPSTF criteria: 50-80 years old, 20 pack-year history
• 2025 European Society of Thoracic Imaging published updated recommendations for LDCT screening result classification
• Global debate: Should never-smokers with other risk factors (radon, occupational, genetics) also be screened?
• Integration of polygenic risk scores into nodule management is an active research frontier

7. SBRT/SABR for High-Risk Non-Surgical Candidates

• Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR): for patients with malignant-appearing nodules who cannot tolerate surgery
• Local control rates >90% for Stage I NSCLC
• This means "too sick to operate" is no longer "too sick to treat"

---

12. SPECIAL POPULATIONS AND TRAPS

Prior Malignancy

• Always biopsy rather than assume metastasis vs. new primary
• Metastatic lesions: classically smooth, multiple, bilateral, lower lobe predominance (blood flow distribution), temporal proximity to primary
• Single lesion in prior malignancy: high chance of new primary, especially with head/neck, lung, uterine, bladder primaries

Immunocompromised Patients

• Higher rate of infectious causes: cryptococcosis, aspergillosis, nocardia
• Septic emboli can present as multiple nodules (NOT technically SPN, but differential)
• Post-transplant lymphoproliferative disease (PTLD) must be considered

Young Patient / Non-smoker

• Probability of malignancy is much lower - granuloma, hamartoma, carcinoid are more likely
• Carcinoid tumors: well-circumscribed, often central, calcified, highly vascular; "salt and pepper" appearance on octreotide scan; associated with carcinoid syndrome only when metastatic

Pregnant Patient

• Radiation dose considerations for CT and PET
• MRI (no contrast) can be used for characterization in some cases
• Management generally deferred unless high suspicion, then VATS can be performed with appropriate precautions in 2nd trimester

---

13. QUESTIONS TO ASK THAT WILL STUMP YOUR PROFESSORS

1. "If FDG-PET has 97% sensitivity for detecting malignancy in a nodule, why do the guidelines say a negative PET cannot rule out malignancy in a 9 mm nodule?"
   • Answer: Because a false-negative PET still has a post-test probability of ~18% malignancy (one study found 18% of PET-negative solid nodules were ultimately malignant). A negative test reduces probability but doesn't eliminate it - Bayesian reasoning applies.
2. "The Fleischner Society says no follow-up for solid nodules <6 mm in low-risk patients. But what if that nodule is in the right upper lobe with a spiculated margin and the patient is a 70-year-old ex-smoker?"
   • Answer: The guidelines explicitly state that "suspicious morphology, upper lobe location, or both can increase cancer risk into the 1-5% range; therefore follow-up at 12 months may be considered depending on comorbidity and patient preference." Guidelines are not algorithms - they require individualization.
3. "What is the volume doubling time paradox with GGOs, and why do we follow them for 5 years instead of 2?"
   • Answer: Solid lung cancers have VDT of 20-400 days. But GGO-type adenocarcinomas (AAH, AIS, MIA) have VDT that can exceed 800-1400 days. A nodule can appear stable for 2 full years and still be pre-invasive or invasive cancer that is simply growing very slowly. The AAH→AIS→MIA→invasive progression is years-long. Two years of stability is NOT reassuring for pure GGOs.
4. "Can a calcified nodule be malignant?"
   • Answer: Yes. Eccentric, stippled, or amorphous calcification can represent cancer that has engulfed a pre-existing calcified granuloma or dystrophic calcification within a tumor. Only central, diffuse, laminated, or popcorn calcification reliably indicates benignity.
5. "Why is FDG-PET essentially useless for ground-glass nodules?"
   • Answer: The cells in GGO lesions (AAH, AIS, MIA) have low metabolic activity even when malignant. FDG-PET sensitivity for GGOs is only ~10%, specificity only ~20%. The biology - low cellularity, lepidic growth pattern, preserved air spaces - means glucose metabolism is too low to generate a positive signal.
6. "In a patient who presents with a 2.5 cm SPN, if CT shows it to be spiculated and PET shows SUVmax of 4.2, what is the next step - biopsy first or surgery first?"
   • Answer: In a patient fit for surgery with high probability (spiculated + PET-positive), proceeding directly to VATS resection is appropriate - it is both diagnostic and therapeutic. CT-guided biopsy is usually reserved for: confirming malignancy before neo-adjuvant chemotherapy, confirming recurrence, high surgical risk patients, or when non-surgical treatment is planned.
7. "What molecular assay can be used non-invasively on blood or BAL to help classify an intermediate-risk nodule?"
   • Answer: Nodify XL2 (plasma protein panel: LG3BP + C163A), Nodify CDT (autoantibody panel), and various microRNA panels. When pretest probability is intermediate and test indicates low risk, invasive biopsy can be safely deferred. This is the most current frontier.

---

14. RAPID-FIRE SUMMARY TABLE

---